418
Views
11
CrossRef citations to date
0
Altmetric
Case History

Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist

Pages 85-93 | Published online: 15 Dec 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Su Han Lum & John D Grainger. (2016) Eltrombopag for the treatment of aplastic anemia: current perspectives. Drug Design, Development and Therapy 10, pages 2833-2843.
Read now

Articles from other publishers (10)

Naotaka Tsutsumi, Zahra Masoumi, Sophie C. James, Julie A. Tucker, Hauke Winkelmann, William Grey, Lora K. Picton, Lucie Moss, Steven C. Wilson, Nathanael A. Caveney, Kevin M. Jude, Cornelius Gati, Jacob Piehler, Ian S. Hitchcock & K. Christopher Garcia. (2023) Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis. Cell 186:19, pages 4189-4203.e22.
Crossref
Nan Shen, Jibing Qiao, Yazhou Jiang, Hanjun Yin, Min Li, Suyue Zhu & Jianqin Li. (2023) Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials. Experimental and Therapeutic Medicine 26:2.
Crossref
Manuel A. Castro, Kristine F. Parson, Ilyas Beg, Mason C. Wilkinson, Kamila Nurmakova, Iliana Levesque, Markus W. Voehler, Michael S. Wolfe, Brandon T. Ruotolo & Charles R. Sanders. (2022) Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain. Journal of Biological Chemistry 298:4, pages 101792.
Crossref
Juan Wang, Min Dai, Qiong Fu & Sheng Chen. (2021) Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease. Scientific Reports 11:1.
Crossref
Yuying Zhu, Liuqing Yang, Jiazhen Xu, Xiyan Yang, Pengwei Luan, Qianfei Cui, Pei Zhang, Feiyun Wang, Ruixiang Li, Xinyue Ding, Lixian Jiang, Guoqiang Lin & Jiange Zhang. (2020) Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein. Acta Pharmaceutica Sinica B 10:8, pages 1414-1425.
Crossref
Hiroaki Tanaka, Kenji Negoro, Takanori Koike, Issei Tsukamoto, Kazuhiro Yokoyama, Jun Maeda, Yusuke Inagaki, Yukinori Shimoshige, Katsutoshi Ino, Kenichiro Ishizu & Taisuke Takahashi. (2020) Discovery and structure-activity relationships study of positive allosteric modulators of the M3 muscarinic acetylcholine receptor. Bioorganic & Medicinal Chemistry 28:13, pages 115531.
Crossref
Huan-Di Liu, Ai-Jie Zhang, Jing-Jing Xu, Ying Chen & Yi-Chun Zhu. (2016) H2S protects against fatal myelosuppression by promoting the generation of megakaryocytes/platelets. Journal of Hematology & Oncology 9:1.
Crossref
James Samanen. 2013. Introduction to Biological and Small Molecule Drug Research and Development. Introduction to Biological and Small Molecule Drug Research and Development 161 203 .
Pradeep Sharma, Caroline J. Butters, Veronica Smith, Robert Elsby & Dominic Surry. (2012) Prediction of the in vivo OATP1B1-mediated drug–drug interaction potential of an investigational drug against a range of statins. European Journal of Pharmaceutical Sciences 47:1, pages 244-255.
Crossref
Anna Tarasova, David Haylock & David Winkler. (2011) Principal signalling complexes in haematopoiesis: Structural aspects and mimetic discovery. Cytokine & Growth Factor Reviews 22:4, pages 231-253.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.